Quarterly report pursuant to Section 13 or 15(d)

Significant Strategic Collaborations (Details Narrative)

v3.22.2.2
Significant Strategic Collaborations (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Rcognized revenue $ 414,250 $ 349,269 $ 1,219,953 $ 828,088  
Revenue 414,250 349,269 1,219,953 828,088  
Research and development expenses 398,803 780,153 3,577,701 1,934,432  
Prepaid Expense and Other Assets, Current 319,103   319,103   $ 479,399
Payments or costs 300,000        
Long term prepayment 300,000   300,000    
Scripps Research [Member] | Scripps Agreement [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Research and development expenses     2,400,000    
Prepaid Expense and Other Assets, Current 0   0   $ 200,000
Collaborative Agreements [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Rcognized revenue     0 0  
Royalty Revenue [Member] | Takeda [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue $ 400,000 $ 300,000 $ 1,200,000 $ 800,000